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Abstract Glucose clamp studies assessing the time–action
profile of long-acting insulin analogues have reported
conflicting results. In an attempt to reconcile the data, we
organised an expert meeting of four leading European clamp
groups, during which consensus was reached on some but
not all points discussed. In this paper, which reflects our
personal views only, we aim to provide guidance for readers
and reviewers on the interpretation of this type of clamp
study and to clarify its inherent limitations.
Glucose clamp studies are either performed manually or
using an automated procedure, but differences in clamp
methodology hardly seem a satisfactory explanation for the
conflicting results. (Un)conscious investigator-related bias,
especially during manual studies, cannot be ruled out, despite
attempts at blinding the study insulin during the clamp.
The duration of action of study insulins is influenced by
many factors, such as glucose and insulin levels prior to
injection, endogenous insulin secretion, insulin dose,
definitions used for onset and end of action, and insulin
sensitivity (which is influenced by the necessity of fasting
during the clamp). These factors limit the translation of
clamp study results into daily practice.
Because of the inherent limitations of the glucose clamp
technique and the lack of reproducibility of the outcomes, its
results should be regarded as no more than an indication of
the clinical action profile of long-acting insulin preparations.
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Abbreviations
EMEA European Medicines Agency
GIR glucose infusion rate
GIRmax maximal glucose infusion rate
PD pharmacodynamic
tGIRmax time to maximal glucose infusion rate
Background
Long-acting insulin analogues were developed to amelio-
rate the distinct peak action, the limited duration of
action and the variable absorption of NPH insulin.
Although they have modest additional clinical benefits
compared with NPH insulin [1, 2], their use is widespread.
This is probably a result of the marketing message that
these analogues are the ideal basal insulin replacement
given their ‘peakless’, nearly 24 h duration of action [1].
This message was supported by a number of isoglycaemic
clamp studies examining the pharmacodynamic (PD) or
time–action profiles of the two currently available long-
acting insulin analogues, insulin glargine and insulin
detemir. However, as we will show, these glucose clamp
data are often difficult to interpret, frequently conflicting
and sometimes misrepresented.
The isoglycaemic clamp technique
The isoglycaemic clamp technique was originally devel-
oped to measure tissue sensitivity to insulin. By keeping the
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glucose concentration constant, the physiological glucose–
insulin feedback loop, whereby the glucose concentration
directly influences the insulin concentration and vice versa,
is disrupted. The amount of i.v. glucose required to
maintain (or ‘clamp’) the glucose concentration at the
euglycaemic target level is equal to the glucose uptake of
all tissues [3] and is expressed as glucose infusion rate
(GIR) over time. When aiming to determine the glucose-
lowering effect of an insulin preparation the recorded GIR
after s.c. injection provides a quantitative measure of its
metabolic activity (i.e. the sum of the decrease in hepatic
glucose production and the increase in glucose uptake) over
time (Fig. 1) [4].
With regard to the registration of new insulin prepara-
tions, the European Medicines Agency (EMEA) considers
data on time–action profiles using the isoglycaemic clamp
technique to be ‘of primary importance to demonstrate
therapeutic equivalence or differences’ between products
[5].
Conflicting clamp data
Glucose clamp studies examining the long-acting insulin
analogues reported conflicting results [6]. For example,
insulin glargine’s time–action profile has been characterised
as being flat [7, 8] and as waxing and waning with a
maximum effect approximately 10 h after injection [9–11].
Also, in one head-to-head study in type 2 diabetic patients
the two long-acting insulin analogues were found to be
comparable [10], whereas another comparison in individ-
uals with type 1 diabetes showed lower total activity and a
shorter duration of action for insulin detemir [12]. Some
have attributed these conflicting findings to differences in
study design, such as the study insulin dose [12], or to
inherent differences in the PD profiles in type 1 vs type 2
diabetic patients [10]. Others have simply labelled incon-
sistent results as ‘outlier findings’ [6]. In an attempt to
reconcile the data, and hypothesising that differences in
study design and definitions used for PD endpoints
contributed to the discrepant outcomes, we organised an
expert meeting.
Clampers’ expert meeting
Four leading European clamp groups involved in studies of
long-acting insulin analogues participated in the expert
meeting. The aim of the meeting was to explore the
influence of various methodological differences between
dissenting groups by discussing the physiological basis of
glucose clamp studies. Our hope was that by emphasising
science in a discussion highly influenced by industry
interests, consensus would be reached on how to perform
and interpret isoglycaemic clamp studies of long-acting
insulin preparations.
Prior to the meeting, discrepancies and similarities
between studies were identified in the relevant publications
and categorised into four topics of discussion: clamp
methodology, study design, outcome measures and statisti-
cal methods (Electronic supplementary material [ESM]
Table 1).
Given the above-mentioned controversies, consensus
was reached on many points during the meeting, such as
the relevant physiological principles, the preferred experi-
mental conditions and the desired mode of reporting of
glucose clamp studies. ESM Table 2 provides a summary of

























Fig. 1 Diagram of an isoglycaemic clamp in an individual with type 1
diabetes, i.e. without endogenous insulin secretion. During the ‘insulin
feedback’ phase, prior to the administration of the study insulin, the
glucose level is stabilised at the clamp glucose target level (5.6 mmol/l).
As the action of the study insulin sets in (t1, onset of action), the i.v.
insulin infusion is gradually decreased (t1 to t2). Starting at this point,
i.v. glucose is required to maintain the target level. Declining study
insulin action is reflected by decreasing glucose requirement (t3 to t4),
ending in termination of the glucose infusion and subsequent rising of
the glucose concentration above the clamp target (t4, end of action)
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of the clamp studies, there were also several points of
disagreement. The present paper expresses our personal
views only. Our aim is to provide guidance on the
interpretation of papers reporting glucose clamp studies
and to clarify the inherent limitations of the technique.
Clamp methodology: Biostator vs manual clamp
Glucose clamp studies can either be performed manually
or by automated procedure using a Biostator (MTB
Medizintechnik, Ulm, Germany). In most manual clamp
studies of long-acting insulin analogues, arterialised plasma
glucose has been measured at intervals of several minutes,
with the investigator adapting the GIR, whereas the
Biostator measures the arterialised blood glucose concen-
tration every minute and adjusts the GIR according to a
negative feedback algorithm based on the deviations of the
glucose measurements from the clamp glucose target [13].
Study glucose targets and outcome measures of these
methods are not interchangeable because blood glucose
concentrations differ by approximately 11% from plasma
values. However, this should not affect clamp study results,
since the amount of glucose infused is not affected by slight
differences in the clamp glucose target. When obtaining
arterialised venous blood the sampling catheter is tradition-
ally placed retrogradely in the vein, but evidence suggests
that this is not strictly necessary [14].
The two techniques also differ in the way the glucose
target is reached prior to the administration of the study
insulin in studies of diabetic patients. During manual
clamps, patients’ glucose levels are lowered slowly by
means of an i.v. infusion of human insulin to reach stable
glucose concentrations. In Biostator studies of individuals
with diabetes, insulin is infused at higher rates to quickly
reduce glucose levels. The glucose infusion is subsequently
started and both infusions are tapered to reach clamp target
levels. As the onset of action of the study insulin is
influenced by the insulin and glucose levels prior to its
injection, this methodological difference may have contrib-
uted to the discrepant results reported for this PD outcome.
However, it is unlikely to have had a major effect on the
time–action profiles after some hours.
To allow proper comparison of the quality of different
studies, it was agreed that this should be reported both as
the mean and the SD of the glucose concentrations of the
individual clamp procedures, and as the mean and SD of
the SDs of the glucose concentrations of the individual
clamp procedures. It was concluded that when clamps are
of high quality (i.e. the mean glucose concentration during
the clamp is close to the target level with few deviations),
automated and manual clamp studies should not result in
different time–action profiles, although definitive experi-
mental evidence for this is lacking. However, during
manual clamps, (un)conscious investigator-related bias
cannot be ruled out, despite attempted blinding of the study
insulin. This may explain why manual clamp studies have
reported different time–action profiles for the same long-
acting insulin analogue [12, 15].
Study design
Whom to clamp: healthy volunteers vs type 1 or type 2
diabetic patients? The duration of action of insulins is most
reliably measured in individuals with type 1 diabetes, as
this excludes interference caused by endogenous insulin
secretion. When not studying type 1 diabetic patients,
endogenous insulin secretion should be suppressed, to
ensure that the glucose requirement is exclusively dictated
by the s.c. administered study insulin, i.e. not stimulated by
erratic upward excursions of the glucose concentration. If it
is not suppressed, endogenous insulin secretion can lead to
augmented GIRs and thus overestimation of the duration of
action. Stimulation of endogenous insulin secretion can be
prevented by clamping at a sub-fasting glucose level, or by
means of a continuous i.v. infusion of human insulin
throughout the clamp (ESM Table 2). The disadvantage of
the latter method is the metabolic effect of the infused
insulin, which increases over time because of the increased
insulin sensitivity resulting from the prolonged fast. This
may again lead to overestimation of the duration of action
of the study insulin (D. K. W. Soon, Exploratory and
Program Medicine, Lilly–NUS Centre for Clinical Pharma-
cology, Singapore, personal communication). Moreover,
suppression of endogenous insulin secretion is incomplete,
with reported reductions in C-peptide levels to about 45%
of the baseline values [16] or ‘>50%’ [8]. However, clamp
studies in healthy volunteers may serve regulatory require-
ments (i.e. to support the registration of a new drug by a
regulatory body such as the EMEA) and as a first indication
of what to expect in diabetic patients.
The main argument in favour of performing clamp
studies in type 2 diabetic patients is that they constitute
the largest clinically relevant population. Although clamp
studies of individuals with type 2 diabetes may overesti-
mate duration of action as a result of the contribution of
endogenous insulin, they reflect the durations that could be
found in clinical practice.
When to clamp and how fasting limits the translation
of clamp study results into daily practice Fasting improves
apparent insulin sensitivity, thereby directly affecting the
time–action profile of the insulin studied. As can be
gathered from ESM Table 1, clamp duration, and therefore
duration of fasting, ranged from 24 to 32 h. Variation in the
1792 Diabetologia (2008) 51:1790–1795
time of day the study insulin was administered also
contributed to differences in the duration of fasting because
the participants in the manual evening dosing studies
received breakfast and lunch with short-acting insulin,
while the individuals who took part in the automated clamp
studies were administered study insulin late in the morning
or at noon, resulting in an extended overnight fast [10, 16,
17]. Such a prolonged fast leads to an increase in insulin
sensitivity, which is also subject to diurnal changes (lowest
in the early morning). Prolonged GIRs resulting from
increased insulin sensitivity complicate the translation of
the (duration of) action found in clamp studies into clinical
practice.
To minimise differences in insulin sensitivity between
and within study participants (when undergoing repeated
clamps), the injection time, duration of fasting and any
residual activity of pre-study insulin injections should be
standardised, and changes in physical activity in the days
preceding the study must be avoided. Carry-over effects
from the participants’ last pre-study basal insulin injection
should be prevented by administration at least 36 h before
clamp start, after which time glucose levels should be
stabilised with a rapid-acting insulin s.c. or i.v. insulin
infusion. The i.v. insulin should be started at least 4–6 h
prior to study insulin administration. During this so-called
‘insulin feedback’, steady-state baseline glucose and insulin
levels are attained. Ideally, the clamp glucose target should
be reached at least 1 h before study insulin administration,
without any glucose infusion during this last hour (Fig. 1).
This can be very difficult to achieve and requires an
operator with substantial experience.
Which insulin dose? The study insulin dose should consti-
tute a clinically relevant dose, reflecting the mean require-
ment of the population under study. In studies investigating
dose–response relationships, the various doses should also
be within the normal requirement range. However, varia-
tions in study insulin dose do not account for the
contradictory findings on the duration of action of the
long-acting analogues, since doses were comparable (0.35
and 0.40 U/kg). This is neatly illustrated in Fig. 1 of a
recent review [6].
Considering the physiological function of basal insulin
secretion (i.e. the suppression of hepatic glucose output), it
should be noted that the ideally formulated long-acting
insulin preparation, given at the optimum dose, in a study
that maintains the ideal glucose target level (5.6 mmol/l),
would result in no glucose infusion (GIR=0 mmol kg−1
min−1), without any escape of glucose concentration from
the target level, by suppressing hepatic glucose sufficiently
but without inducing a decrease in glucose level. Strictly
speaking, when glucose has to be infused during a clamp,
the study insulin has already been ‘overdosed’. On the other
hand, basal insulin needs when fasting during a clamp are
different from day-to-day needs. Thus, again, although
clamp studies may give us an impression of time–action
profiles, translating the results into daily life is difficult.
Single vs repeated study injections The vast majority of
studies have examined the time–action profile of a single
s.c. injection, and only recently have two studies investigated
PD profiles in a steady-state situation, i.e. after several days of
s.c. administration of study insulin [12, 18]. Obviously, for
long-acting insulin preparations with a duration of action
over 24 h, it is especially important to study steady-state
time–action profiles as well. This should be done in diabetic
patients and, again, the study insulin dose should be
clinically appropriate for the study participants.
Limitations of any definition of duration of action
As discussed above, GIR may increase at the end of clamp
procedures as a result of increasing insulin sensitivity
associated with fasting, diurnal changes in insulin sensitiv-
ity and/or the contribution of endogenous insulin [6, 13].
Other factors complicating the determination of the (abso-
lute) duration of action of long-acting insulin preparations
are their relatively low overall metabolic action at a given
point in time and their very gradual onset and end of action.
In addition, onset of action is difficult to determine because
it is greatly influenced by the glucose and insulin levels
prior to study insulin administration. Finally, it is not
possible to define onset of action in steady-state conditions
after repeated administration of long-acting insulin ana-
logues. In single-injection studies, onset of action is best
defined as the time after study insulin administration at
which the i.v. insulin is gradually decreased (t1 of Fig. 1).
Declining study insulin action is reflected by a decreas-
ing glucose requirement, ending in the termination of the
i.v. glucose infusion and the subsequent spontaneous
increase in the glucose concentration to above the clamp
target. As the purpose of basal insulin preparations is to
control fasting glucose at about 5.6 mmol/l (100 mg/dl), the
clinically appropriate definition of end of action is when no
glucose infusion is required to prevent the glucose falling
below that concentration (point t4 of Fig. 1). However, the
attendees at the expert meeting did not deem such a
glucose level suitable to define end of action, as insulin
action can seemingly disappear, only to reappear shortly
thereafter. They defined end of action as the time after
study insulin administration at which the glucose concen-
tration increases to >8.3 mmol/l (150 mg/dl). However, the
problem of disappearing and reappearing action potentially
occurs at every chosen glucose cut-off value, and
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8.3 mmol/l is clearly not a clinically appropriate glucose
target level.
Summarising individual data in one time–action profile
In most reports of glucose clamp studies, individual time–
action profiles are averaged and depicted as a single mean
curve. When applying this method it is essential that the
GIRs for the study participants in whom end of action
occurred before the end of study (by definition, GIR=
0 mmol kg−1 min−1) are included in the calculation of the
mean curve. Also, the number of participants that remain to
constitute the mean curve, i.e. those in whom the end of
action of the study insulin does not occur before the end of
the clamp procedure, should be mentioned on the x-axis
of the mean time–action profile. As information is lost by
averaging individual curves, it was agreed that in addition
to mean curves, individual PD profiles should be published,
e.g. as an online appendix.
The GIR curves are usually smoothed, and the end-
points, maximal glucose infusion rate (GIRmax) and time to
GIRmax (tGIRmax), are derived from these smoothed profiles.
These differ considerably from the unsmoothed GIR curve
(Fig. 2), and the area under the GIR curve (GIR-AUC)
should be calculated from raw data. Automated and manual
clamp studies require different approaches to curve
smoothing, as the glucose concentration is measured every
minute by the Biostator vs every 3–5 min during manual
clamps. As a result, GIR is less variable in manual
clamping compared with automated studies, and therefore
needs ‘soft’ smoothing. Data from Biostator-aided clamps
require ‘hard’ smoothing by means of a regression
technique. At present it is not clear whether different
methods of smoothing create relevant differences in
observed time–action profiles.
Conclusions
There was a high level of consensus among four leading
European clamp groups about the relevant physiological
principles, the preferred experimental conditions and the
desired mode of reporting of glucose clamp studies. The
described differences in clamp methodology hardly seem a
satisfactory explanation for the conflicting results. The
possibility that unintentional manipulation by the investi-
gator during manual clamp studies may have contributed to
discrepant outcomes cannot be ruled out. Whatever the
reason for the contradictory results, the fact that the study
results of one group cannot be confirmed by another limits
the scientific validity of the clamp method for assessment
of the time–action profile of long-acting insulins. Thus, the
results of glucose clamp studies should be regarded as no
more than an indication of the metabolic action of these
insulin preparations.
Clinical trials are essential to determine the clinical
action of insulin preparations. For example, when looking
at the duration of action, a study showed that in 15–30% of
patients with type 1 diabetes, the action of insulin glargine
does not last up to 24 h and a second long-acting insulin
injection is beneficial in these instances [19]. When looking
at the peak effect, a clinical study demonstrated that insulin
glargine is associated with a peak in hypoglycaemia rate at
6–12 h after administration, indicating at least some peak
effect [20], which forcefully argues against a flat profile for
insulin glargine. Similarly, injection of insulin detemir in
the morning is associated with higher nocturnal and lower
late-afternoon glucose levels, compared with detemir
administration in the evening [21]. In conclusion, time–
action profiles of long-acting insulins determined by
glucose clamp studies can be translated into clinical
practice to only a limited extent, and clinical trials are
essential to determine clinical action profiles.
Epilogue
On 19 April 2007, experts from four leading European
clamp groups participated in a meeting chaired by the last
author of this paper. The minutes of the meeting were
approved by all participants after minor revisions. Subse-
quently, these minutes were rewritten into a scientific paper.
All but one group commented and agreed to the paper. This
group felt unable to co-author a paper ‘with authors
between whom disagreements largely exceed agreements’.
























Fig. 2 Time-course of GIR in response to insulin glargine (black
curve) and NPH insulin (grey curve) administration, showing both the
raw data and the smoothed profiles. To convert GIR in mg kg−1 min−1
into mmol kg−1 min−1, multiply by 0.0055. Reproduced with
permission from Rave et al. [22]
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‘had covered the discussions very well’, also withdrew as a
co-author. Following this, we extensively rewrote the paper
to produce the present article.
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